Abstract
Original language | English |
---|---|
Journal | Cancer Epidemiology, Biomarkers & Prevention |
Volume | 16 |
Issue number | 7 |
Pages (from-to) | 616-628 |
Number of pages | 13 |
ISSN | 1055-9965 |
DOIs | |
Publication status | Published - 2011 |
Keywords
- Biochemical markers
- Type I collagen
- Liver fibrosis
- Protease-cleaved neo-epitope
- MMP-2,-9,-13
- Translational science
- Bile duct ligation
- CCL4
- Rat model
- Breast cancer
- Prostate cancer
- Bone metastases
Cite this
}
A novel marker for assessment of liver matrix remodeling: An enzyme-linked immunosorbent assay (ELISA) detecting a MMP generated type I collagen neo-epitope (C1M). / Leeming, Diana Julie; He, Y.; Veidal, S. S.; Nguyen, Q. H. T.; Larsen, D. V.; Koizumi, M.; Segovia-Silvestre, T.; Zhang, C.; Zheng, Q.; Sun, S.; Cao, Y.; Barkholt, Vibeke; Hägglund, Per; Bay-Jensen, A. C.; Qvist, P.; Karsdal, M. A.
In: Cancer Epidemiology, Biomarkers & Prevention, Vol. 16, No. 7, 2011, p. 616-628.Research output: Contribution to journal › Journal article › Research › peer-review
TY - JOUR
T1 - A novel marker for assessment of liver matrix remodeling: An enzyme-linked immunosorbent assay (ELISA) detecting a MMP generated type I collagen neo-epitope (C1M)
AU - Leeming, Diana Julie
AU - He, Y.
AU - Veidal, S. S.
AU - Nguyen, Q. H. T.
AU - Larsen, D. V.
AU - Koizumi, M.
AU - Segovia-Silvestre, T.
AU - Zhang, C.
AU - Zheng, Q.
AU - Sun, S.
AU - Cao, Y.
AU - Barkholt, Vibeke
AU - Hägglund, Per
AU - Bay-Jensen, A. C.
AU - Qvist, P.
AU - Karsdal, M. A.
PY - 2011
Y1 - 2011
N2 - A competitive enzyme-linked immunosorbent assay (ELISA) for detection of a type I collagen fragment generated by matrix metalloproteinases (MMP) -2, -9 and -13, was developed (CO1-764 or C1M). The biomarker was evaluated in two preclinical rat models of liver fibrosis: bile duct ligation (BDL) and carbon tetra chloride (CCL4)-treated rats. The assay was further evaluated in a clinical study of prostate-, lung-and breast-cancer patients stratified according to skeletal metastases. A technically robust ELISA assay specific for a MMP-2, -9 and -13 neo-epitope was produced and seen to be statistically elevated in BDL rats compared to baseline levels as well as significantly elevated in CCL4 rats stratified according to the amount of total collagen in the livers. CO1-764 levels also correlated significantly with total liver collagen and type I collagen mRNA expression in the livers. Finally, the CO1-764 marker was not correlated with skeletal involvement or number of bone metastases. This ELISA has the potential to assess the degree of liver fibrosis in a non-invasive manner.
AB - A competitive enzyme-linked immunosorbent assay (ELISA) for detection of a type I collagen fragment generated by matrix metalloproteinases (MMP) -2, -9 and -13, was developed (CO1-764 or C1M). The biomarker was evaluated in two preclinical rat models of liver fibrosis: bile duct ligation (BDL) and carbon tetra chloride (CCL4)-treated rats. The assay was further evaluated in a clinical study of prostate-, lung-and breast-cancer patients stratified according to skeletal metastases. A technically robust ELISA assay specific for a MMP-2, -9 and -13 neo-epitope was produced and seen to be statistically elevated in BDL rats compared to baseline levels as well as significantly elevated in CCL4 rats stratified according to the amount of total collagen in the livers. CO1-764 levels also correlated significantly with total liver collagen and type I collagen mRNA expression in the livers. Finally, the CO1-764 marker was not correlated with skeletal involvement or number of bone metastases. This ELISA has the potential to assess the degree of liver fibrosis in a non-invasive manner.
KW - Biochemical markers
KW - Type I collagen
KW - Liver fibrosis
KW - Protease-cleaved neo-epitope
KW - MMP-2,-9,-13
KW - Translational science
KW - Bile duct ligation
KW - CCL4
KW - Rat model
KW - Breast cancer
KW - Prostate cancer
KW - Bone metastases
U2 - 10.3109/1354750x.2011.620628
DO - 10.3109/1354750x.2011.620628
M3 - Journal article
VL - 16
SP - 616
EP - 628
JO - Cancer Epidemiology, Biomarkers & Prevention
JF - Cancer Epidemiology, Biomarkers & Prevention
SN - 1055-9965
IS - 7
ER -